- Company
- Stephen Walter, Boehringer Ingelheim's CEO, will resign
- by Eo, Yun-Ho Jun 11, 2021 05:53am
- Boehringer Ingelheim's CEO, Stephen Walter will be replaced. According to related industries, Stephen Walter, the current CEO of Boehringer Ingelheim in Korea, will resign after this month (June). The successor is now known as the head of an Austrian corporation and will be officially appointed in July. Boehringer Ingelheim Korea Corpor
- Company
- Hemlibra's reimbursement criteria to be rediscussed
- by Nho, Byung Chul Jun 11, 2021 05:53am
- Interest is rising as the Health Insurance Review and Assessment Service (HIRA) plans to call an expert advisory meeting to discuss the more effective operation of immune tolerance induction (ITI·antibody removal) therapies. At the end of this month, HIRA’s Pharmaceutical Standard Department plans to conduct deliberations to come up wit
- Policy
- 1 in 5 people received COVID-19 vaccinations in Korea
- by Kim, Jung-Ju Jun 11, 2021 05:53am
- With the number of daily COVID-19 cases constantly in the 500 range, over 10 million people in Korea have received one or more shots of COVID-19 vaccines. This is nearly 20% of the total population, in other words, 1 out of 5 people in Korea have now been vaccinated. In the midst of the increasing outdoor activities and the upcoming summe
- Policy
- Moderna vaccine, 100% effective for Asians in clinical trial
- by Lee, Tak-Sun Jun 11, 2021 05:53am
- Moderna's COVID-19 vaccine has been shown to be 100% effective in Asian clinical trials. However, there is a limit to reaching a meaningful conclusion because there are fewer test subjects. The minutes of the Central Pharmaceutical Affairs Review Committee, released by the MFDS on the 7th, contain this information. The Central Pharmaceutic
- Policy
- OTC combination drug with APAP-IBU, not approved again
- by Lee, Tak-Sun Jun 11, 2021 05:53am
- OTC approval of APAP-IBU complex has failed again. Experts who participated in the review objected to the permission on the grounds that safety issues had not been resolved. According to the Central Pharmaceutical Affairs Review Committee minutes released on the 7th, seven out of 10 members opposed the OTC approval of Acetaminophen-Ibuprof
- Company
- What is the most likely treatment for Alzheimer's?
- by Kim, Jin-Gu Jun 10, 2021 05:55am
- As Biogen's Aducanumab (Aduhel) was approved by the U.S. Food and Drug Administration (FDA) for the first time in 18 years as a treatment for Alzheimer's, competition for development of Aducanumab. Currently, Roche, Eli Lilly, Ezai, Johnson and Johnson are considered companies that have started to develop treatments for Alzheimer's. In
- Company
- Korean novel drug Leclaza may become cheaper than Tagrisso
- by Eo, Yun-Ho Jun 10, 2021 05:55am
- The daily drug cost of Korea's novel anticancer drug 'Leclaza' is expected to be set at a level that is around &8361;10,000 cheaper than ‘Tagrisso.’ Dailypharm found that the price of Yuhan Corp.’s 3rd generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Leclaza (lazertinib) was set at &8361;69,000 per e
- Company
- Former GSK GM Yoo-Seok Hong to head D&D Pharmatech
- by An, Kyung-Jin Jun 10, 2021 05:55am
- Yoo-Seok Hong, former General Manager of GSK Korea will be joining the leadership of the biotech company, D&D Pharmatech. On the 9th, D&D Pharmatech had announced that the company has appointed Yoo-Seok Hong as its new CEO. Hong is a seasoned expert with extensive experience in marketing and business management at multinational pharmaceut
- Company
- Once again, the fear of impurities
- by Chon, Seung-Hyun Jun 10, 2021 05:55am
- Fear of impurities is spreading again in the domestic pharmaceutical industry. There is a high risk that the aftermath of large-scale withdrawal of impurities from Canada will also damage Korea. Pharmaceutical companies are nervous in that it is a new type of impurity that is different from the one that has built a verification system over the p
- Policy
- 5 companies' developing vaccines have completed Phase I
- by Kim, Jung-Ju Jun 10, 2021 05:55am
- The development products of five companies that are developing domestic COVID-19 vaccines have all been found to have completed phase 1 clinical trial and entered the next stage Depending on the product, some vaccines are aimed at entering phase 3 clinical trials as early as next month (July). The MOHW reported the status of vaccine develo
